Jose Vicent Pons, CEO, Dr. Julen Oyarzabal, Co-Founder and CSOSyngoi, a pioneering biotech company based in Europe, is redefining how DNA is manufactured. Its fully enzymatic, cGMP-compliant platform produces linear, synthetic DNA (oDNA), eliminating the biological constraints of bacterial fermentation. This approach enables faster, cleaner, and more scalable production—while also optimizing and customizing synthetic DNA for a wide variety of therapeutic approaches in the development of genetic medicines.
“Our goal was to create a platform that unlocks the full potential of synthetic DNA for therapeutic applications,” says Dr. Julen Oyarzabal, Syngoi’s Chief Scientific Officer and co-founder. “By moving away from plasmid DNA and embracing a fully cell-free, enzymatic process rooted in synthetic biology, we’re giving developers the speed, purity, and customization their projects need to reach the patient while maintaining the highest standards of quality and performance.”
Moving Beyond Plasmid Constraints
Plasmid DNA (pDNA) has long served as the standard template for genetic medicine development. But its drawbacks—long production timelines, reliance on bioreactors, and biological contaminants like endotoxins and antibiotic resistance genes—now pose growing obstacles to efficient progress.
Syngoi’s technology addresses these limitations directly. Its cell-free platform delivers linear synthetic DNA at both research and clinical scales in as little as five working days. The resulting DNA is highly pure, free from bacterial elements, and ready to integrate into mRNA manufacturing, genome editing, and other genetic medicine workflows.
Flexible, Custom DNA for Every Application
Syngoi’s system is designed to support diverse therapeutic needs. DNA is available in single- or double-stranded formats and can be enhanced with customizable adaptor sequences—short, non-coding oligonucleotides that improve performance across key steps such as transfection, delivery, and transcription.
-
With a cell-free, enzymatic platform for synthetic DNA, Syngoi is helping innovators accelerate development, reduce risk, and achieve clinical success
Measurable Impact at Accelerated Speed
A standout example of Syngoi’s real-world impact came through its partnership with Afrigen Biologics under CEPI’s 100 Days Mission. Syngoi’s synthetic DNA enabled a complete mRNA vaccine development workflow—from DNA synthesis to drug product release—in just 43 days, dramatically reducing the timeline compared to traditional plasmid-based methods.
This rapid turnaround not only supported the project’s pandemic response goals but also delivered cleaner, more transcription-ready DNA. Enhanced product quality was confirmed by strong mRNA integrity and functional protein expression, demonstrating that speed did not come at the expense of performance.
Across client programs, Syngoi’s synthetic DNA continues to deliver reliable results, enabling developers to move from design to production with greater agility and confidence.
Scalable Support for All Stages
For early-stage biotech teams and academic innovators, Syngoi offers accessible, scalable DNA manufacturing without the need for internal production infrastructure. Its modular process supports both small-batch and gram-scale output, allowing clients to scale as their programs evolve.
Syngoi also offers a unique choice of starting materials: clients can use conventional plasmid DNA or PURE synthetic DNA, produced de novo via oligonucleotide assembly—both supported by Syngoi’s proprietary enzymatic workflow. This dual strategy offers maximum flexibility in design and execution.
A Partner in Innovation
What distinguishes Syngoi is not only its technology, but also its client-first approach. The company provides scientific guidance, regulatory insight, and hands-on support to help clients integrate synthetic DNA seamlessly into complex manufacturing workflows.
“We see ourselves as strategic partners—not just suppliers,” says José Vicent Pons, Syngoi’s Chief Executive Officer. “Our clients rely on us for quality, speed, and adaptability. But more than that, they value the insight and support we bring to help them meet aggressive milestones and move confidently toward the clinic.”
The Path Ahead
Syngoi’s mission is to make synthetic DNA a high-performance, accessible resource for developers of genetic medicines around the world. With its robust enzymatic platform, customizable product offerings, and science-led service model, the company is enabling the next generation of genetic medicines to reach patients faster, more reliably, and with greater impact.
Linear Synthetic DNA Solution Info
What distinguishes Syngoi among Top Synthetic DNA Manufacturing Companies?
Syngoi has earned recognition among Top Synthetic DNA Manufacturing Companies through its fully cell-free, enzymatic platform for producing linear synthetic DNA designed for advanced genetic medicine applications. Unlike traditional plasmid-based systems, it manufactures optimized linear DNA (oDNA) using a proprietary enzymatic process that removes bacterial fermentation entirely, enabling faster, cleaner and more customizable DNA production. The company’s approach is specifically built for next-generation therapies where DNA quality, purity and scalability are critical for downstream applications such as gene therapy and mRNA production. (lifesciencesrevieweurope.com )
How does Syngoi’s linear synthetic DNA technology work?
A cell-free enzymatic manufacturing system defines its core innovation. Syngoi produces double-stranded linear DNA containing only the gene of interest, enhanced with proprietary “adaptors” that optimize biological performance. These adaptors can influence stability, immune response and intracellular delivery efficiency depending on project requirements. This flexible design allows Synthetic DNA Manufacturing Companies like Syngoi to tailor DNA constructs for specific therapeutic applications rather than relying on fixed, standardized templates. (syngoi.com )
Why is Syngoi relevant to advanced gene and cell therapy development?
Modern genetic medicine requires DNA templates that are faster to produce, more consistent and free from bacterial impurities. Syngoi addresses this need through Synthetic DNA Manufacturing Companies solutions that support gene therapy, genome editing, CAR-T development, DNA vaccines and mRNA production workflows. Its linear DNA format eliminates many of the production bottlenecks associated with plasmid DNA, helping accelerate preclinical and clinical development timelines in highly regulated therapeutic environments. (lifesciencesreview.com )
What role do Syngoi’s proprietary adaptors play in DNA optimization?
Adaptors are a defining feature of the company’s platform. These non-coding sequences are added to the ends of the gene of interest to modify key DNA properties such as stability, immunogenic response and transcription efficiency. Within Synthetic DNA Manufacturing Companies, this level of modular customization is significant because it allows researchers to fine-tune DNA behavior without altering the genetic payload itself, preserving functional integrity while improving performance in therapeutic systems. (syngoi.com )
How does Syngoi support scalability and GMP manufacturing needs?
Scalability is embedded into its enzymatic production model. Syngoi operates a cGMP-compliant, cell-free manufacturing process capable of producing DNA from milligram to gram scale in a significantly shorter timeframe compared to traditional fermentation methods. This allows Synthetic DNA Manufacturing Companies like Syngoi to support early-stage research as well as clinical-grade production without changing core manufacturing principles, ensuring consistency across development stages. (lifesciencesrevieweurope.com )
Why has Syngoi gained recognition in synthetic biology and genetic medicine?
Syngoi has gained recognition due to its ability to fundamentally re-engineer how synthetic DNA is produced for therapeutic use. Its elimination of bacterial systems, combined with customizable DNA architecture and rapid production timelines, positions it as a key innovator in next-generation genetic medicine infrastructure. The company’s integration of scalability, regulatory alignment and functional DNA optimization reinforces its standing among leading Synthetic DNA Manufacturing Companies. (syngoi.com )
